Evaluation of intravenous voriconazole in patients with compromised renal function

BACKGROUND: Incorporation of the solubilizing excipient, sulfobutylether-β-cyclodextrin (SBECD), in the intravenous (IV) formulation of voriconazole has resulted in the recommendation that this formulation be used with caution in patients with creatinine clearances (Cl(cr)) < 50 mL/min. This stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Lilly, Craig M, Welch, Verna L, Mayer, Thomas, Ranauro, Paul, Meisner, Joanne, Luke, David R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584958/
https://www.ncbi.nlm.nih.gov/pubmed/23320795
http://dx.doi.org/10.1186/1471-2334-13-14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584958/
https://www.ncbi.nlm.nih.gov/pubmed/23320795
http://dx.doi.org/10.1186/1471-2334-13-14

Ejemplares similares